Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.08. | Evaxion A/S - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
27.08. | Evaxion to present at several conferences during the second half of 2025 | 313 | GlobeNewswire (Europe) | Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months
COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)... ► Artikel lesen | |
14.08. | Evaxion Biotech ADS GAAP EPS of -$0.02 | 2 | Seeking Alpha | ||
14.08. | Evaxion announces business update and second quarter 2025 financial results | 406 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and... ► Artikel lesen | |
13.08. | Insights Ahead: Evaxion Biotech's Quarterly Earnings | 1 | Benzinga.com | ||
11.08. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
11.08. | Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 | 264 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
25.07. | Evaxion A/S - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
EVAXION Aktie jetzt für 0€ handeln | |||||
25.07. | Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 403 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will be presenting two-year clinical... ► Artikel lesen | |
11.07. | Evaxion finalizes €3.5 million debt-to-equity deal with EIB | 3 | Investing.com | ||
11.07. | Evaxion schließt Debt-to-Equity-Vereinbarung mit EIB über 3,5 Millionen Euro ab | 5 | Investing.com Deutsch | ||
11.07. | Evaxion A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
11.07. | Evaxion finalizes agreement with EIB to convert debt into equity | 369 | GlobeNewswire (Europe) | Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth... ► Artikel lesen | |
02.07. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
01.07. | Evaxion Biotech: Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio | 389 | GlobeNewswire (Europe) | Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief... ► Artikel lesen | |
25.06. | Evaxion entwickelt neuen Impfstoff gegen Gruppe-A-Streptokokken | 6 | Investing.com Deutsch | ||
25.06. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
25.06. | Evaxion Biotech: Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus | 314 | GlobeNewswire (Europe) | Initial computational analysis demonstrated that Evaxion's AI-Immunology platform can identify novel vaccine targets to combat
Group A Streptococcus (GAS)New vaccine program is added to Evaxion's... ► Artikel lesen | |
03.06. | Evaxion secures Gates Foundation grant for polio vaccine | 2 | Investing.com | ||
03.06. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 83,20 | -0,06 % | OpenDoor, Almonty Industries, BioNTech - Große Chancen außerhalb der Tech-Blase | Während in der vergangenen Woche der Nasdaq 100 mit den führenden Technologiewerten weiter an Momentum verlor, konnte das Krisenmetall Gold bei 3.586 USD je Unze ein neues historisches Hoch feiern.... ► Artikel lesen | |
EVOTEC | 5,948 | +2,23 % | Evotec Aktie: Ein Schimmer der Hoffnung | Entspannung bei der Evotec Aktie? Die Biotech-Aktie war in den vergangenen Wochen wieder einmal gefallen, hat in den letzten Tagen aber im Bereich 5,70/5,78 Euro sichtlich charttechnische Unterstützung... ► Artikel lesen | |
QIAGEN | 38,395 | -1,26 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
CUREVAC | 4,518 | -0,62 % | BioNTech schmiert nach Meldungen über neue Impfeinschränkungen in den USA ab, auch Pfizer und Moderna geraten unter Druck, CureVac bleibt unbeeindruckt | Schon seit Monaten geht der US-Gesundheitsminister Robert F. Kennedy aktiv gegen Impfungen vor, über die er sich seit Jahren kritisch äußert. Bereits umgesetzt wurden Änderungen bei den Leitlinien.... ► Artikel lesen | |
PAION | 0,015 | -39,20 % | UNGLAUBLICHE Sondermeldung bei Paion Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
AMGEN | 233,55 | +0,09 % | Führungswechsel bei Amgen in Deutschland: Carolina Correa übernimmt die Geschäftsführung der Amgen Deutschland GmbH | München (ots) - Zum 1. September 2025 hat Carolina Correa die Geschäftsführung der Amgen Deutschland GmbH von Manfred Heinzer übernommen, der die deutsche Landesorganisation zuvor fünf Jahre lang erfolgreich... ► Artikel lesen | |
NOVAVAX | 6,814 | -0,84 % | Why Avoid Pfizer, BioNTech, Novavax, and Moderna | ||
STRYKER | 321,30 | +0,19 % | Stryker launches Incompass total ankle system | ||
BIOGEN | 122,05 | +0,16 % | Große Kursgewinne für die Biogen-Aktie (125,6827 €) | Die Aktie von Biogen zählt heute zu den großen Gewinnern an der Börse. Der Titel steigt deutlich. Grund zur Freude haben Aktionäre von Biogen: Das Papier weist derzeit einen Wertanstieg von 3,43 Prozent... ► Artikel lesen | |
CRISPR THERAPEUTICS | 49,400 | +0,41 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 | ||
OCUGEN | 1,020 | +0,34 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
APOGEE THERAPEUTICS | 36,860 | -0,05 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen |